Great Lakes Advisors LLC Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Great Lakes Advisors LLC reduced its holdings in Supernus Pharmaceuticals by 3.5%, owning approximately 0.29% of the company valued at around $5.36 million after the sale of 5,977 shares.
• Insider selling was significant, with SVP Frank Mottola and CFO Timothy C. Dec selling a combined total of 25,780 shares, representing drastic decreases in their ownership percentages.
• Wall Street analysts have a mixed outlook on Supernus Pharmaceuticals, with target prices varying between $36.00 and $46.00, indicating both a potential for growth and a cautious stance.

Great Lakes Advisors LLC reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 163,580 shares of the specialty pharmaceutical company's stock after selling 5,977 shares during the period. Great Lakes Advisors LLC owned 0.29% of Supernus Pharmaceuticals worth $5,357,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SUPN. Raiffeisen Bank International AG bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth about $25,000. Financial Management Professionals Inc. bought a new position in shares of Supernus Pharmaceuticals in the 1st quarter worth about $30,000. Versant Capital Management Inc raised its position in shares of Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after acquiring an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Supernus Pharmaceuticals in the 1st quarter worth about $41,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth about $42,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SUPN shares. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Piper Sandler lifted their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Friday, August 29th. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $43.00.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $689,726.96. This represents a 47.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director directly owned 46,307 shares in the company, valued at $1,956,933.82. The trade was a 13.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 241,506 shares of company stock worth $10,466,794. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Trading Down 2.6%

Supernus Pharmaceuticals stock traded down $1.20 during midday trading on Friday, reaching $45.46. The stock had a trading volume of 415,075 shares, compared to its average volume of 624,694. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $46.78. The company has a market capitalization of $2.55 billion, a P/E ratio of 39.53 and a beta of 0.79. The company has a fifty day moving average price of $39.42 and a two-hundred day moving average price of $34.58.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.